Pancreatic Cancer — RepurpOS | OpenSourceMedicine

Disease overview

Alterations

126

Molecular (A)

100

Clinical (B–E)

Direct drugs

254

Via biomarker

422

Natural agents

Natural products

Merged ranked

672

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, Examine.com · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Essentially zero; one of the highest cancer mortality rates; 5-year survival ~12% overall; only 15-20% have resectable disease at diagnosis

Best-intervention remission

Resectable: surgery (Whipple) + FOLFIRINOX adjuvant: 54.4 months median OS (PRODIGE 24, vs 35.0 months gemcitabine); BRCA-mutant metastatic: olaparib maintenance after platinum-based: 7.4 vs 3.8 months PFS (POLO); neoadjuvant chemotherapy: may convert 20-30% of borderline-resectable to resectable

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Very large — minimal survival improvement for most patients over past 20 years; imaging and liquid biopsy for early detection is the biggest opportunity

Primary barrier

biological + access (early detection)

Barrier detail: Pancreatic cancer is detected late (70-80% at Stage III-IV) due to absence of early symptoms and screening; CA19-9 is insufficiently sensitive/specific for early detection; BRCA1/2 and other HRR mutation testing is not universal; KRAS G12D/G12V targeted agents represent a genuine pipeline advance

Last SoC change: 2023 — NALIRIFOX first-line for metastatic PDAC (NAPOLI-3 — modest improvement); 2020 olaparib maintenance for BRCA-mutant; 2019 FOLFIRINOX adjuvant standard; gemcitabine + nab-paclitaxel first-line since 2013; gemcitabine monotherapy since 1997

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005192

Right to Try Relevance Critical

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Pancreatic Cancer may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

Phase 3: 33, Phase 2: 7

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

126

Actionable

Pipeline Compounds (Top 6)

Algenpantucel-L, Bevacizumab, Capecitabine, Celecoxib, Cisplatin, Curcumin

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

Showing 80 of 126 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abdominal pain	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Anorexia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Back pain	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Breast carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Chronic fatigue	Functional	Functional test	—	—	Moderate	HPO, Monarch	HPO
Colon cancer	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Diabetes mellitus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Elevated circulating hepatic transaminase concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Exocrine pancreatic insufficiency	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Extrahepatic cholestasis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Functional intestinal obstruction	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hepatosplenomegaly	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Increased level of L-fucose in urine	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Intermittent diarrhea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Intestinal pseudo-obstruction	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Jaundice	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Lymphadenopathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Melanoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nausea and vomiting	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neoplasm of the liver	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neoplasm of the pancreas	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Ovarian carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pancreatic adenocarcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Peritoneal abscess	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Poor appetite	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Weight loss	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ABL2 ABL proto-oncogene 2, non-receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ABO ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	Ensembl Open Targets
ACVR1 activin A receptor type 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ACVR1B activin A receptor type 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ACVR2A activin A receptor type 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AFF3 ALF transcription elongation factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AR androgen receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARHGAP26 Rho GTPase activating protein 26	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID1A AT-rich interaction domain 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID1B AT-rich interaction domain 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATM ATM serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BMPR1A bone morphogenetic protein receptor type 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRCA1 BRCA1 DNA repair associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRCA2 BRCA2 DNA repair associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRIP1 BRCA1 interacting DNA helicase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
C11orf65 chromosome 11 open reading frame 65	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1D calcium voltage-gated channel subunit alpha1 D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CAMTA1 calmodulin binding transcription activator 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDC73 cell division cycle 73	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDH11 cadherin 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK6 cyclin dependent kinase 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN2A cyclin dependent kinase inhibitor 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHEK2 checkpoint kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTRB2 chymotrypsinogen B2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CUX1 cut like homeobox 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EBF1 EBF transcription factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EGFR epidermal growth factor receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB4 erb-b2 receptor tyrosine kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ESR1 estrogen receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EXT1 exostosin glycosyltransferase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EXT2 exostosin glycosyltransferase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR2 fibroblast growth factor receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FHIT fragile histidine triad diadenosine triphosphatase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FOXP1 forkhead box P1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GNAS GNAS complex locus	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPC3 glypican 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2A glutamate ionotropic receptor NMDA type subunit 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HIP1 huntingtin interacting protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK1 Janus kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KDM6A lysine demethylase 6A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KDR kinase insert domain receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KIT KIT proto-oncogene, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KMT2C lysine methyltransferase 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KMT2D lysine methyltransferase 2D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KRAS KRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LEF1 lymphoid enhancer binding factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LPP LIM domain containing preferred translocation partner in lipoma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LRP1B LDL receptor related protein 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAML2 mastermind like transcriptional coactivator 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP2K4 mitogen-activated protein kinase kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP3K13 mitogen-activated protein kinase kinase kinase 13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAPK1 mitogen-activated protein kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MECOM MDS1 and EVI1 complex locus	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MITF melanocyte inducing transcription factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
3,3',4',5-TETRACHLOROSALICYLANILIDE		Gene-targeted
ABIRATERONE ACETATE	inhibitor	Gene-targeted
ACETAZOLAMIDE	None	Gene-targeted
ACETOPHENAZINE		Gene-targeted
ALCLOFENAC		Gene-targeted
ALCLOMETASONE DIPROPIONATE		Gene-targeted
AMCINONIDE		Gene-targeted
AMDINOCILLIN		Gene-targeted
AMIODARONE HYDROCHLORIDE		Gene-targeted
AMLEXANOX		Gene-targeted
AMLODIPINE BESYLATE		Gene-targeted
AMPHETAMINE	None	Gene-targeted
ANHYDROUS TACROLIMUS		Gene-targeted
APALUTAMIDE	inhibitor; inhibitor	Gene-targeted
APIGENIN		Gene-targeted
APOMORPHINE		Gene-targeted
ASTEMIZOLE		Gene-targeted
ATALUREN		Gene-targeted
ATEZOLIZUMAB		Gene-targeted
ATRACURIUM BESYLATE		Gene-targeted
ATROPINE		Gene-targeted
AVELUMAB		Gene-targeted
AZACITIDINE		Gene-targeted
AZARIBINE		Gene-targeted
BECLOMETHASONE DIPROPIONATE		Gene-targeted
BENAZEPRIL HYDROCHLORIDE		Gene-targeted
BENDAMUSTINE		Gene-targeted
BENORILATE		Gene-targeted
BETAMETHASONE		Gene-targeted
BETAMETHASONE DIPROPIONATE		Gene-targeted
BETAMETHASONE SODIUM PHOSPHATE		Gene-targeted
BETAMETHASONE VALERATE		Gene-targeted
BICALUTAMIDE	inhibitor; inhibitor	Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BIFONAZOLE		Gene-targeted
BINIMETINIB		Gene-targeted
BISACODYL		Gene-targeted
BITHIONOL		Gene-targeted
BITHIONOLATE SODIUM		Gene-targeted
BLEOMYCIN		Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
CIPROFLOXACIN	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
METHOXSALEN	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PHENYTOIN	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SIROLIMUS	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ABIRATERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALCLOFENAC Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMDINOCILLIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMLEXANOX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APIGENIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
APOMORPHINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASTEMIZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATALUREN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATRACURIUM BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZARIBINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENDAMUSTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENORILATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BIFONAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BINIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BISACODYL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOLATE SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BLEOMYCIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BORTEZOMIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BROMOCRIPTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BROMOCRIPTINE MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BUPRENORPHINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BUTAMBEN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Sources	Links
ALGENPANTUCEL-L	Cell therapy	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BEVACIZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CAPECITABINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CELECOXIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CISPLATIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DALTEPARIN SODIUM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ERLOTINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ERLOTINIB HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
EXATECAN MESYLATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FLUOROURACIL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FOLINIC ACID	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
G17DT IMMUNOGEN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GIMERACIL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IRINOTECAN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IRINOTECAN HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LEUCOVORIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LEUCOVORIN CALCIUM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
MASITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
METHYLNALTREXONE BROMIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
NIMOTUZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
OTERACIL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
OXALIPLATIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PACLITAXEL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
RUBITECAN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
SARGRAMOSTIM	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
SORAFENIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TEGAFUR	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TERTOMOTIDE	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TINZAPARIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
URIDINE TRIACETATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ADEBRELIMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ALDOXORUBICIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
AMATUXIMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ANETUMAB RAVTANSINE	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
APATORSEN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
APRICOXIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ABIRATERONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing via ABL2	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ALCLOFENAC Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMDINOCILLIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMLEXANOX Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing via ABL2	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
APALUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
APIGENIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
APOMORPHINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ASTEMIZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATALUREN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
ATRACURIUM BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AZARIBINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENDAMUSTINE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
BENORILATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BICALUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ABL2	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BIFONAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BINIMETINIB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
BISACODYL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOLATE SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BLEOMYCIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	—	DGIdb	—

Natural Products

1 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Vitamin E: Alpha Tocopherol Natural product Animal Study This study clearly show the crucial role of vitamin E on growth in juve…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed		—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.